Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set ...

More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

The pharma major is also strengthening its presence in the central nervous system (CNS) therapeutic area, Vohra stated ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Eli Lilly has outpaced Ozempic-maker Novo Nordisk in the race to develop new incretin drugs. The company is set to capture 50% of the $95 billion obesity market by 2050.

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.